Astellas Discontinues Development of Alzheimer's Disease Compound FK962.Tokyo, Japan, July 18, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Astellas Pharma Astellas Pharma Inc. (アステラス製薬株式会社 Inc. today announced that it has decided to discontinue dis·con·tin·ue v. dis·con·tin·ued, dis·con·tin·u·ing, dis·con·tin·ues v.tr. 1. To stop doing or providing (something); end or abandon: development of the Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. compound FK962. Astellas started Phase-II trials for FK962 for Alzheimer's disease in the US and Canada. After careful review of the Phase-II interim analysis clinical data on FK962, Astellas has decided to discontinue further development of FK962 in Alzheimer's disease since the data reviewed did not indicate clear efficacy of the compound for the treatment of mild to moderate Alzheimer's disease. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion